As part of its forward integration strategy, Farmson Basic Drugs has extended its paracetamol expertise into Directly Compressible (DC) Paracetamol granules, providing tablet manufacturers with ready-to-use formulations. Paracetamol DC granules are a tablet-ready form of the drug that can be directly compressed into pills without a separate granulation step. Farmson’s venture into DC granules demonstrates its commitment to meeting evolving customer needs by offering end-to-end solutions – from API production to formulation-ready intermediates. This move simplifies the supply chain for pharma companies, who can source both the raw API and the pre-formulated granules from a single reliable manufacturer.

Farmson’s DC granule facility is built to world-class standards and carries an EU-GMP certification for quality compliance. It boasts a production capacity of 3,600 metric tons per annum of Paracetamol DC granules, with highly flexible batch sizes ranging from 200 kg up to 2,000 kg (scalable further to 6,000 kg) per batch. Every batch undergoes stringent in-process and quality checks to ensure uniform particle size, excellent flowability, and compressibility – critical attributes for consistent tablet manufacturing. This means pharmaceutical companies using Farmson’s DC granules can achieve high-speed compression with minimal weight variation and robust tablet quality.

Key factors that make Farmson a leader in Paracetamol DC manufacturing include:

• Advanced Granulation Technology: The DC production lines are fully integrated and utilize GLATT technology (a leading fluid-bed granulation system), ensuring uniform mixing and granule quality in each lot. The result is granules with reliable hardness and low friability, translating to fewer processing issues during tableting.
  
• Pharmacopeial Compliance: Farmson’s DC granules are formulated to meet the specifications of major pharmacopeias (EP, BP, USP, IP), making them globally accepted for use in pharmaceutical products. Despite being a composite product (paracetamol plus excipient matrix), each grade is tested to ensure it adheres to strict quality requirements.
  
• Multiple Grades & Customization: The company produces a wide range of DC grades – including 97%, 96%, 90%, 84% (and even ~83.3%) paracetamol content variants – to suit different formulation needs. Whether a client needs higher active loading or specific granule size distribution, Farmson can provide the appropriate grade. Moreover, tailor-made DC granules can be developed by Farmson’s team for bespoke requirements.
  
• In-House Formulation R&D: Farmson operates a dedicated Formulation R&D (FR&D) laboratory to continually enhance its DC granules and develop new grades. This laboratory drives innovation in granulation processes, improving granule performance (e.g., better dissolution or compression characteristics) and ensuring the product keeps pace with emerging tablet technologies. The FR&D capability means Farmson can collaborate with clients to optimize the granules for specific drug formulations.
  
• Packaging and Global Supply: Understanding the importance of handling and logistics, Farmson offers flexible, safe packaging options for DC granules. Clients can receive the product in 25 kg or 50 kg fiber drums for convenient use, or in large 500–600 kg bulk bags for industrial-scale needs. This ensures stability during transit and easy integration into the client’s production line, anywhere in the world.
  

Farmson’s integrated approach (from manufacturing the base paracetamol API to converting it into DC granules) gives it tight control over quality at every stage and a cost advantage that it can pass to customers. By providing “drum-to-feeder” compressible granules, Farmson helps tablet manufacturers eliminate a processing step, reduce their operational costs, and accelerate production timelines. This level of convenience, combined with Farmson’s hallmark quality, is why Farmson’s DC granules are trusted by pharmaceutical companies globally.

In conclusion, Farmson’s Paracetamol DC granule facility exemplifies excellence in forward integration. It merges the company’s deep knowledge of paracetamol chemistry with advanced formulation engineering. The outcome is a high-quality, easy-to-use product that upholds Farmson’s reputation for purity, consistency, and compliance. By setting industry benchmarks in this niche, Farmson has reinforced its position not just as a bulk API supplier, but as a comprehensive partner in the pharmaceutical supply chain for paracetamol-based medicines.